Editor-in-Chief: Alex A. Adjei, MD, PhD, FACP
ISSN: 1556-0864
Online ISSN: 1556-1380
Frequency: 12 issues / year
Ranking: Oncology 26/202
Respiratory System 5/53
Impact Factor: 5.800
Editor's Choice

In December, we highlight three articles. Tsao et al provide an overview of advances in lung cancer pathology over the last forty years and highlight the role of IASLC in these advances - Forty Years of the International Association for Study of Lung Cancer (IASLC) Pathology Committee. Asiedu and colleagues discuss genetic aberrations in carcinoid cell lines that were generated and sequenced by their group - Generation and sequencing of pulmonary carcinoid tumor cell lines, and finally Litvak et al discuss the clinical characteristics as well as clinical outcomes in patients with thymic carcinoma - Clinical Characteristics and Outcomes for Patients with Thymic Carcinoma: Evaluation of Masaoka Staging. Dr Nicolas Girard has an insightful editorial accompanying the Litvak article as well as a second article on a phase II study of amrubicin in thymic carcinoma. Alex A. Adjei, MD, PhD, Editor-in-Chief

Actions
View
  • Open Access
  • Free Access
  • Purchase Access
  • Partial Access
Actions
View
Login

Quick Poll

For coverage of this subject, please see Boland JM et al, J Thorac Oncol, 8: 574 -581, 2013

A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
A healthy 60-year old male, “never-smoker” with no co-morbidities is referred to you with stage IV NSCLC (NOS) . There is inadequate tissue to make a firm histologic diagnosis, and no molecular studies have been performed. You send the patient for endo-bronchial ultrasound and additional tissue biopsies. Successful tissue acquisition and additional testing reveal moderately differentiated adenocarcinoma with mucinous features. FISH analysis reveals an EML4-ALK translocation. Regarding the molecular features of this tumor, which of the following statements is/are true?
 Submit
 Clear
 Results
Foreign Language Editions

JTO is proud to present translations of its content into French and Chinese. We sincerely thank  Jean-Louis Pujol, Wu Yilong, and Tony Mok for their work on the French and Chinese editions.  

French, Selected Articles

French JTO, Vol 1 Issue 1

French JTO, Vol 1 Issue 2

French JTO, Vol 1 Issue 3

 

Chinese, Selected Articles

Chinese JTO, Vol 2 Issue 2

 

Call for Videos
JTO accepts videos as supplemental content to articles. Submission guidelines online.
Other Ways to Connect

Twitter
twitter.com/JTOonline

 



Visit JTO.org on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.

 For additional oncology content, visit LWW Oncology Journals on Facebook.